Alpha-synuclein measured in cerebrospinal fluid from patients with Alzheimer’s disease, mild cognitive impairment, or healthy controls: a two year follow-up study

BACKGROUND: α-Synuclein has been proposed as a potential biomarker for Alzheimer’s disease (AD) and amnestic mild cognitive impairment (aMCI). However, results from α-synuclein measurements in cerebrospinal fluid (CSF) have been inconclusive, and to our knowledge, longitudinal studies of changes pri...

Descripción completa

Detalles Bibliográficos
Autores principales: Berge, Guro, Sando, Sigrid B., Albrektsen, Grethe, Lauridsen, Camilla, Møller, Ina, Grøntvedt, Gøril R., Bråthen, Geir, White, Linda R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5031325/
https://www.ncbi.nlm.nih.gov/pubmed/27653987
http://dx.doi.org/10.1186/s12883-016-0706-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5031325/
https://www.ncbi.nlm.nih.gov/pubmed/27653987
http://dx.doi.org/10.1186/s12883-016-0706-0

Ejemplares similares